Danaher Corp
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Diagnostics — Core Sales Growth by Year
Diagnostics — Core Sales Growth (%) (%)
Danaher Diagnostics — Core Sales Growth: 1.5% in FY2025, down 1.5 pts from a year earlier.
Where the FY2025 figure comes from
Source: Danaher IR — nongaap_2025Q4 ↗
Includes Cepheid, Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, HemoCue, Mammotome, and Masimo (from 10/06/2026).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diagnostics — Core Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.5% | -1.5 pts | Danaher IR — nongaap_2025Q4 ↗ |
| FY2024 | Dec 31, 2024 | 3.0% | +13.5 pts | Danaher IR — nongaap_2024Q4 ↗ |
| FY2023 | Dec 31, 2023 | -10.5% | -24.0 pts | Danaher IR — nongaap_2023Q4 ↗ |
| FY2022 | Dec 31, 2022 | 13.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
Breakdown
What makes up diagnostics — Core Sales Growth
Cite this data
StockData. (2026). Danaher Diagnostics — Core Sales Growth (%), annual FY2022–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/core-sales-growth-diag
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.